700
700 peer-reviewed publications describing our TB test as demonstrating excellent performance in a wide variety of settings
75
M Providing workflows that enabled the testing of more than 75 million individuals for COVID-19
1500
Introducing over 1,500 new antibodies, kits, and reagents annually for life science research
2
M Supplying more than two million scientists across pharma, biotech, and academia with Revvity's software solutions
33
M Screening 33 million babies annually for life-threatening diseases across 110 countries